Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Meteoric Biopharmaceuticals Pvt. Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
A Preliminary Investigation of the Safety and Effectiveness of Oral Probiotics Supplementation for Reducing the Risk of Kidney Stone in Adults with Recurrent Kidney Stone Colic or Acute Episode of Colicky Pain: An Open-Label, Single-Arm, Prospective, Interventional, Proof-of-Science Study.
14 adults, with recurrent kidney stone colic or acute episode of colicky pain will be enrolled to ensure 12 subjects complete the study
Potential subjects will undergo screening based on predefined inclusion and exclusion criteria only after obtaining written informed consent.
Subjects shall be instructed to visit the facility for the following scheduled visits:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Recurrent Kidney Stone with Colicky Pain | Experimental | Take one slow-release capsule twice a day, after meal, orally. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MetProrenes | Other | Take one slow-release capsule twice a day, after meal. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in the colicky pain | Evaluate the effect of the test treatment in term of change in the colicky pain determined using the VAS scoring where 0 indicates no pain and 10 indicates severe pain | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Urine Calcium | Assessment of the effectiveness of the test treatment in terms of changes in Urine Calcium examined by urinalysis after 24h-urine collection | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Urine Sodium | Assessment of the effectiveness of the test treatment in terms of changes in Urine Sodium examined by urinalysis after 24h-urine collection | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Urine Oxalate | Assessment of the effectiveness of the test treatment in terms of changes in Urine Oxalate examined by urinalysis after 24h-urine collection | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Urine pH | Assessment of the effectiveness of the test treatment in terms of changes in Urine pH examined by urinalysis after 24h-urine collection | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Urine R/M | Assessment of the effectiveness of the test treatment in terms of changes in Urine R/M examined by urinalysis after 24h-urine collection |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Haemoglobin | Assessment of the safety of the test treatment in terms of abnormal changes in Haemoglobin | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Haematocrit |
Not provided
Inclusion Criteria:
The subject is an adult aged between 18 to 55 years old.
The subject has a history of recurrent kidney stone colic or acute episode of colicky pain on clinical examination by Physician.
Subject having refrigerator at their home for storage of test product.
The subject is willing to provide written informed consent and comply with study procedures, including overnight stay for 24 hours at the study centre during both visits.
The subject is willing to abide by the study protocol and restrictions, including abstaining from using any other oral or topical treatments for kidney stone colic during the study period.
The subject is in a stable medical condition, not requiring immediate intervention or hospitalization.
If the subject is female, she is willing to use a highly effective method of contraception throughout the clinical investigation.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Maheshvari N Patel | Contact | 09909013236 | maheshvari@novobliss.in | |
| Sheetal J Khandwala | Contact | bd@novobliss.in |
| Name | Affiliation | Role |
|---|---|---|
| Dr. Nayan K Patel | NovoBliss Research Pvt Ltd | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
An Open-Label, Single-Arm, Prospective, Interventional, Proof-of-Science Study
Not provided
Not provided
Not provided
Not provided
| On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
Assessment of the safety of the test treatment in terms of abnormal changes in Haematocrit.
| On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Red Blood count | Assessment of the safety of the test treatment in terms of abnormal changes in Red Blood Count. | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Packed Cell Volume | Assessment of the safety of the test treatment in terms of abnormal changes in Packed cell volume Count. | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Red Blood count morphology | Assessment of the safety of the test treatment in terms of abnormal changes in Red Blood Count morphology. | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Mean corpuscular volume | Assessment of the safety of the test treatment in terms of abnormal changes in Mean corpuscular volume | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in mean corpuscular hemoglobin | Assessment of the safety of the test treatment in terms of abnormal changes in mean corpuscular hemoglobin | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in mean corpuscular hemoglobin concentration | Assessment of the safety of the test treatment in terms of abnormal changes in mean corpuscular hemoglobin concentration | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in red blood cell distribution width | Assessment of the safety of the test treatment in terms of abnormal changes in red blood cell distribution width | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Total WBC count | Assessment of the safety of the test treatment in terms of abnormal changes in Total WBC count. | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Differential WBC count | Assessment of the safety of the test treatment in terms of abnormal changes in Differential WBC count. | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Platelet count | Assessment of the safety of the test treatment in terms of abnormal changes in Platelet count. | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in mean platelet volume | Assessment of the safety of the test treatment in terms of abnormal changes in mean platelet volume. | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Plateletcrit | Assessment of the safety of the test treatment in terms of abnormal changes in Plateletcrit. | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in platelet distribution width | Assessment of the safety of the test treatment in terms of abnormal changes in platelet distribution width. | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes inSerum Creatinine | Assessment of the safety of the test treatment in terms of abnormal changes in Serum Creatinine. | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Serum Glutamic Pyruvic Transaminase | Assessment of the safety of the test treatment in terms of abnormal changes in Serum Glutamic Pyruvic Transaminase | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |
| Changes in Serum Glutamic-Oxaloacetic Transaminase | Assessment of the safety of the test treatment in terms of abnormal changes in Serum Glutamic-Oxaloacetic Transaminase | On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days). |